Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991107 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production
A Phase 1 study of Insulin Resistance, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00991107: Completed Phase 1 study of Insulin Resistance, sponsored by Harbor Therapeutics.
NCT00991107 is a Phase 1 study of Insulin Resistance that has completed, run by Harbor Therapeutics. The registered enrollment target is 5 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00991107, a Phase 1 study of Insulin Resistance, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.
Conditions Studied
Interventions
- DRUG HE3286
Study Locations (1)
Louisiana
- Clinical Site - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
What the finished NCT00991107 record still lists
NCT00991107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which HE3286 is the first listed.
NCT00991107 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT00991107 about?
NCT00991107 is a clinical study titled "A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production". The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant ...
What is the current status of trial NCT00991107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-09. Estimated completion is 2010-08.
What conditions does trial NCT00991107 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT00991107?
The interventions under investigation include: HE3286 (DRUG).
Who is sponsoring clinical trial NCT00991107?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00991107 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00991107's enrollment target sits among peer trials
5 120th of 120 higher than 1 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Graded Insulin Suppression Test P&F
RECRUITING · Phase 1
-
Diazoxide Suppression Test P&F Study
RECRUITING · Phase 1
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia